letrozole has been researched along with Hormone-Dependent Neoplasms in 135 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2." | 9.34 | TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. ( Carey, LA; Delossantos, JF; Forero-Torres, A; Grizzle, WE; Li, Y; Lin, NU; Liu, MC; LoBuglio, AF; Myers, RM; Nanda, R; Puhalla, S; Roberts, BS; Rugo, HS; Saleh, MN; Storniolo, AM; Vaklavas, C; Varley, KE, 2020) |
| "To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer." | 9.30 | Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. ( Bernhard, J; Coates, AS; Colleoni, M; Dellapasqua, S; Di Leo, A; Gelber, RD; Gianni, L; Goldhirsch, A; Gray, KP; Johansson, H; Kammler, R; Maibach, R; Munzone, E; Rabaglio-Poretti, M; Regan, MM; Ribi, K; Rubino, D; Ruepp, B; Viale, G, 2019) |
| "17 randomly assigned 5,187 postmenopausal, hormone-receptor-positive patients with early breast cancer who completed 5 years of tamoxifen to receive either letrozole or placebo." | 9.13 | Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. ( Goss, PE; He, Z; Ingle, JN; Martino, S; Muss, HB; Palmer, MJ; Pater, JL; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D; Whelan, TJ, 2008) |
| "17 trial examined the efficacy of letrozole (LET) started within 3 months of 5 years of adjuvant tamoxifen in postmenopausal hormone receptor-positive early-stage breast cancer." | 9.13 | Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. ( Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D, 2008) |
| "In the primary core analysis of BIG 1-98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole versus tamoxifen in postmenopausal women with hormone receptor-positive (HR+) early breast cancer, letrozole significantly improved disease-free survival by 19% and reduced the risk of breast cancer recurrence by 28% and distant recurrence by 27%." | 9.13 | Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. ( Delea, TE; El-Ouagari, K; Karnon, J; Sofrygin, O, 2008) |
| "Four thousand nine hundred twenty-two of the 8,028 postmenopausal women with receptor-positive early breast cancer randomly assigned (double-blind) to the BIG 1-98 trial were assigned to 5 years of continuous adjuvant therapy with either letrozole or tamoxifen; the remainder of women were assigned to receive the agents in sequence." | 9.12 | Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. ( Castiglione-Gertsch, M; Chirgwin, J; Coates, AS; Colleoni, M; Del Mastro, L; Forbes, JF; Gelber, RD; Goldhirsch, A; Jakobsen, EH; Keshaviah, A; Láng, I; Mauriac, L; Mouridsen, H; Nogaret, JM; Paridaens, R; Pienkowski, T; Price, KN; Smith, I; Thürlimann, B; Wardley, A, 2007) |
| "The BIG 1-98 trial is a large, randomized, independently conducted clinical trial designed to compare the efficacy of upfront letrozole versus tamoxifen monotherapy and to compare sequential or up-front use of letrozole and/or tamoxifen as an early adjuvant therapy for patients with early breast cancer." | 9.12 | Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. ( Koeberle, D; Thuerlimann, B, 2007) |
| "The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen." | 9.11 | A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. ( Castiglione-Gertsch, M; Coates, AS; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wardly, A, 2005) |
| "We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy." | 9.10 | A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. ( Abrams, JS; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Therasse, P; Tu, D, 2003) |
| "In this Phase I trial, 23 heavily pretreated postmenopausal patients with metastatic breast cancer received letrozole at doses ranging from 0." | 9.08 | Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. ( Adlercruetz, H; Brady, C; Demers, LM; Grossberg, H; Harvey, HA; Kambic, KB; Lipton, A; Santen, RJ; Trunet, PF, 1995) |
| "In the first-line setting, the phase II PALbociclib: Ongoing trials in the Management of breast cAncer (PALOMA)-1 trial randomized patients to receive letrozole alone or letrozole plus palbociclib 125 mg daily for 3 weeks, followed by 1 week off, as initial therapy for advanced breast cancer." | 8.91 | Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. ( Berger, MJ; Lustberg, MB; Mangini, NS; Ramaswamy, B; Wesolowski, R, 2015) |
| " Lapatinib has recently been approved, in combination with capecitabine, for the treatment of HER2-positive metastatic breast cancer patients failing trastuzumab therapy." | 8.85 | Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. ( Guarneri, V, 2009) |
| "Letrozole is a highly selective, nonsteroidal, third-generation aromatase inhibitor approved for first-line and extended adjuvant therapy in postmenopausal women with hormone-responsive, early-stage breast cancer." | 8.83 | Letrozole : in postmenopausal hormone-responsive early-stage breast cancer. ( Keam, SJ; Scott, LJ, 2006) |
| "Therapeutics that interfere with estrogen receptor function (antiestrogens, eg, tamoxifen; aromatase inhibitors, eg, letrozole) have contributed to a dramatic reduction in breast cancer mortality; however, not all estrogen-receptor-positive breast cancers respond." | 8.83 | Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. ( Lane, HA; Lebwohl, D, 2006) |
| "A consecutive cohort of ER( +)/HER2( -) advanced breast cancer patients who received palbociclib between 2017 and 2018 was analyzed." | 7.96 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. ( Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J, 2020) |
| "To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -positive breast cancer." | 7.78 | Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. ( A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L, 2012) |
| "Endocrine agents, such as letrozole, are established in the treatment of hormone-dependent breast cancer." | 7.75 | Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. ( Anderson, TJ; Dixon, JM; Evans, DB; Krause, A; Larionov, A; Miller, WR; Renshaw, L; Sing, T; Walker, JR, 2009) |
| "Letrozole after 5 years of adjuvant tamoxifen results in a significant reduction in risk of recurrence from estrogen receptor (ER) positive breast cancer." | 7.74 | Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. ( Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C, 2007) |
| "Genistein (GEN), a soy isoflavone, stimulates growth of estrogen-dependent human tumor cells (MCF-7) in a preclinical mouse model for postmenopausal breast cancer." | 7.74 | Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. ( Doerge, DR; Hartman, JA; Helferich, WG; Ju, YH; Kwak, J; Woodling, KA, 2008) |
| "Five years with the aromatase inhibitors letrozole or anastrozole is clinically superior to 5 years tamoxifen in postmenopausal women with early breast cancer." | 7.74 | Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. ( Barghout, V; Delea, T; Karnon, J, 2008) |
| "In Breast International Group (BIG) 1-98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole versus tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer, letrozole significantly improved disease-free survival by 19% and reduced risk of breast cancer recurrence by 28% and distant recurrence by 27%." | 7.74 | Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. ( Barghout, V; Delea, TE; Karnon, J; Papo, NL; Sofrygin, O; Thomas, SK, 2007) |
| "Two third-generation aromatase inhibitors, letrozole and anastrozole, and the antiestrogen tamoxifen, were compared for growth-inhibiting activity in two estrogen receptor (ER)-positive aromatase-overexpressing human breast cancer cell lines, MCF-7aro and T-47Daro." | 7.73 | Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. ( Chen, S; Itoh, T; Kijima, I, 2005) |
| "To compare the efficiency of adjuvant therapy with aromatase inhibitors or with tamoxifen in postmenopausal women with operable breast cancer and positive estrogen receptors." | 7.73 | Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. ( Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C, 2006) |
| "The antiestrogen tamoxifen has potent activity against estrogen receptor-positive breast cancer, but two nonsteroidal aromatase inhibitors, letrozole and anastrozole, show considerable advantages over tamoxifen with respect to patient survival and tolerability." | 7.72 | Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A, 2004) |
| "To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmenopausal breast cancer." | 7.72 | Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L, 2004) |
| "Put-analysis in 40 patients with breast cancer, to chanalicular infiltrated, eligible were treated in a prospective study, to double blind person, using per os: letrozol, 2." | 6.76 | [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer]. ( Amador, DD; Font López, KC; Novoa Vargas, A, 2011) |
| "Breast cancer is a leading cause of cancer death among women worldwide." | 6.44 | Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer. ( Dodwell, D; Williamson, D, 2008) |
| "Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2." | 5.34 | TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. ( Carey, LA; Delossantos, JF; Forero-Torres, A; Grizzle, WE; Li, Y; Lin, NU; Liu, MC; LoBuglio, AF; Myers, RM; Nanda, R; Puhalla, S; Roberts, BS; Rugo, HS; Saleh, MN; Storniolo, AM; Vaklavas, C; Varley, KE, 2020) |
| "Letrozole (2." | 5.31 | Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. ( Chen, G; Cohen, MH; Johnson, JR; Li, N; Pazdur, R, 2002) |
| "To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer." | 5.30 | Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. ( Bernhard, J; Coates, AS; Colleoni, M; Dellapasqua, S; Di Leo, A; Gelber, RD; Gianni, L; Goldhirsch, A; Gray, KP; Johansson, H; Kammler, R; Maibach, R; Munzone, E; Rabaglio-Poretti, M; Regan, MM; Ribi, K; Rubino, D; Ruepp, B; Viale, G, 2019) |
| "Women with early-stage breast cancer initiating AI therapy were enrolled onto a multicenter, prospective, open-label randomized trial of exemestane versus letrozole." | 5.16 | Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. ( Azzouz, F; Desta, Z; Flockhart, DA; Hayden, J; Hayes, DF; Henry, NL; Lemler, S; Li, L; Nguyen, AT; Stearns, V; Storniolo, AM; Tarpinian, K; Yakim, E, 2012) |
| "Postmenopausal women with hormone-sensitive breast cancer were given three months of letrozole 2." | 5.13 | Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. ( Chow, LW; Loo, WT; Toi, M; Yip, AY, 2008) |
| "In the primary core analysis of BIG 1-98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole versus tamoxifen in postmenopausal women with hormone receptor-positive (HR+) early breast cancer, letrozole significantly improved disease-free survival by 19% and reduced the risk of breast cancer recurrence by 28% and distant recurrence by 27%." | 5.13 | Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. ( Delea, TE; El-Ouagari, K; Karnon, J; Sofrygin, O, 2008) |
| "17 trial, conducted by the National Cancer Institute of Canada Clinical Trials Group, 5170 breast cancer patients (median age = 62 years; range = 32-94 years) who were disease free after approximately 5 years of adjuvant tamoxifen treatment were randomly assigned to treatment with letrozole (2583 women) or placebo (2587 women)." | 5.13 | Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. ( Chapman, JA; Goss, PE; Ingle, JN; Meng, D; Muss, HB; Palmer, M; Parulekar, W; Shepherd, L; Yu, C, 2008) |
| "17 randomly assigned 5,187 postmenopausal, hormone-receptor-positive patients with early breast cancer who completed 5 years of tamoxifen to receive either letrozole or placebo." | 5.13 | Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. ( Goss, PE; He, Z; Ingle, JN; Martino, S; Muss, HB; Palmer, MJ; Pater, JL; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D; Whelan, TJ, 2008) |
| "17 trial examined the efficacy of letrozole (LET) started within 3 months of 5 years of adjuvant tamoxifen in postmenopausal hormone receptor-positive early-stage breast cancer." | 5.13 | Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. ( Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D, 2008) |
| "Third-generation nonsteroidal aromatase inhibitors (AIs), letrozole and anastrozole, are superior to tamoxifen as initial therapy for early breast cancer but have not been directly compared in a head-to-head adjuvant trial." | 5.12 | A decade of letrozole: FACE. ( O'Shaughnessy, J, 2007) |
| "Aromatase inhibitors are considered standard adjuvant endocrine treatment of postmenopausal women with hormone receptor-positive breast cancer, but it remains uncertain whether aromatase inhibitors should be given upfront or sequentially with tamoxifen." | 5.12 | Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. ( Castiglione-Gertsch, M; Coates, AS; Debled, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Láng, I; Mauriac, L; Monnier, A; Mouridsen, H; Nogaret, JM; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Viale, G; Wardley, A; Zabaznyi, N, 2007) |
| "Four thousand nine hundred twenty-two of the 8,028 postmenopausal women with receptor-positive early breast cancer randomly assigned (double-blind) to the BIG 1-98 trial were assigned to 5 years of continuous adjuvant therapy with either letrozole or tamoxifen; the remainder of women were assigned to receive the agents in sequence." | 5.12 | Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. ( Castiglione-Gertsch, M; Chirgwin, J; Coates, AS; Colleoni, M; Del Mastro, L; Forbes, JF; Gelber, RD; Goldhirsch, A; Jakobsen, EH; Keshaviah, A; Láng, I; Mauriac, L; Mouridsen, H; Nogaret, JM; Paridaens, R; Pienkowski, T; Price, KN; Smith, I; Thürlimann, B; Wardley, A, 2007) |
| "Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer." | 5.12 | Letrozole in the extended adjuvant setting: MA.17. ( Goss, PE, 2007) |
| "The BIG 1-98 trial is a large, randomized, independently conducted clinical trial designed to compare the efficacy of upfront letrozole versus tamoxifen monotherapy and to compare sequential or up-front use of letrozole and/or tamoxifen as an early adjuvant therapy for patients with early breast cancer." | 5.12 | Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. ( Koeberle, D; Thuerlimann, B, 2007) |
| "The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen." | 5.11 | A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. ( Castiglione-Gertsch, M; Coates, AS; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wardly, A, 2005) |
| "We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy." | 5.10 | A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. ( Abrams, JS; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Therasse, P; Tu, D, 2003) |
| "Five hundred sixty-two estrogen receptor-positive metastatic breast cancer patients were randomized to first-line hormone therapy with either letrozole or tamoxifen." | 5.10 | Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. ( Ali, SM; Brady, C; Carney, W; Chaudri-Ross, HA; Demers, L; Harvey, HA; Leitzel, K; Lipton, A; Wyld, P, 2003) |
| "In this Phase I trial, 23 heavily pretreated postmenopausal patients with metastatic breast cancer received letrozole at doses ranging from 0." | 5.08 | Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. ( Adlercruetz, H; Brady, C; Demers, LM; Grossberg, H; Harvey, HA; Kambic, KB; Lipton, A; Santen, RJ; Trunet, PF, 1995) |
| "We performed a network meta-analysis for a comprehensive analysis of 6 first-line endocrine monotherapies (letrozole, anastrozole, exemestane, tamoxifen, fulvestrant 250 mg and 500 mg) for HR+ HER2- metastatic or locally advanced breast cancer in postmenopausal patients." | 4.95 | Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. ( He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S, 2017) |
| "In the first-line setting, the phase II PALbociclib: Ongoing trials in the Management of breast cAncer (PALOMA)-1 trial randomized patients to receive letrozole alone or letrozole plus palbociclib 125 mg daily for 3 weeks, followed by 1 week off, as initial therapy for advanced breast cancer." | 4.91 | Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. ( Berger, MJ; Lustberg, MB; Mangini, NS; Ramaswamy, B; Wesolowski, R, 2015) |
| " A meta-analysis revealed an advantage for AIs over tamoxifen in the monotherapy setting for recurrence but not breast cancer mortality, and an advantage in both of these parameters for switching to an AI after several years of tamoxifen." | 4.89 | Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors. ( Ingle, JN, 2013) |
| " Lapatinib has recently been approved, in combination with capecitabine, for the treatment of HER2-positive metastatic breast cancer patients failing trastuzumab therapy." | 4.85 | Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. ( Guarneri, V, 2009) |
| "Third-generation aromatase inhibitors (AIs), including letrozole, are now standard therapy for initial adjuvant endocrine treatment of postmenopausal women with early breast cancer." | 4.84 | Understanding the BIG results: Insights from the BIG 1-98 trial analyses. ( Wardley, AM, 2008) |
| "A systematic review was undertaken to review the evidence for the use of third-generation aromatase inhibitors (anastrozole, letrozole and exemestane) as adjuvant therapy for post-menopausal women with early-stage, hormone receptor-positive breast cancer and to develop and support recommendations for their use, with regard to three areas: aromatase inhibitors compared to tamoxifen, aromatase inhibitors in sequence with tamoxifen for a total of five years, and aromatase inhibitors given after five years of tamoxifen therapy." | 4.84 | Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. ( Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M, 2008) |
| "The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer." | 4.84 | Safety of aromatase inhibitors in the adjuvant setting. ( Perez, EA, 2007) |
| "Therapeutics that interfere with estrogen receptor function (antiestrogens, eg, tamoxifen; aromatase inhibitors, eg, letrozole) have contributed to a dramatic reduction in breast cancer mortality; however, not all estrogen-receptor-positive breast cancers respond." | 4.83 | Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. ( Lane, HA; Lebwohl, D, 2006) |
| "Letrozole is a highly selective, nonsteroidal, third-generation aromatase inhibitor approved for first-line and extended adjuvant therapy in postmenopausal women with hormone-responsive, early-stage breast cancer." | 4.83 | Letrozole : in postmenopausal hormone-responsive early-stage breast cancer. ( Keam, SJ; Scott, LJ, 2006) |
| "The latest generation of nonsteroidal aromatase inhibitors (anastrozole and letrozole) has been approved by the US Food and Drug Administration for use in the first- and second-line treatment of postmenopausal women with hormone receptor-positive (or unknown) breast cancer." | 4.82 | Pharmacokinetics of third-generation aromatase inhibitors. ( Lønning, P; Martoni, A; Pfister, C; Zamagni, C, 2003) |
| "Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy." | 4.82 | A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. ( Rose, C, 2003) |
| " (1) The presentation of the first results of the study BIG 1-98 -- letrozole as adjuvant, endocrine therapy in postmenopausal women with hormone-sensitive breast cancer -- showed a relative risk reduction in the disease-free survival of 19% when compared to tamoxifen." | 4.82 | [Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)]. ( Senn, HJ; Thürlimann, B, 2005) |
| "New aromatase inhibitors (AI) (second-generation: formestane and fadrozole; third-generation: letrozole, anastrozole, vorozole, and exemestane) have been tested in several controlled clinical trials after tamoxifen failure in metastatic breast carcinoma (MBC)." | 4.82 | New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. ( Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Milella, M; Mottolese, M; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E, 2005) |
| "Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen (Nolvadex) as the hormonal therapy of choice in estrogen-receptor-positive, postmenopausal, metastatic breast cancer." | 4.81 | Nonsteroidal and steroidal aromatase inhibitors in breast cancer. ( Hamilton, A; Volm, M, 2001) |
| "The new generation of selective aromatase inhibitors (anastrozole, letrozole and exemestane) offer a significant efficacy and safety advantage over both older agents in this class (aminoglutethimide) and the progestins (megestrol acetate (MA)), as second-line treatment for postmenopausal women with advanced hormone-dependent breast cancer who have failed on tamoxifen therapy." | 4.81 | A summary of second-line randomized studies of aromatase inhibitors. ( Buzdar, AU, 2001) |
| "With recent results showing letrozole and anastrozole to be superior to tamoxifen as initial therapy for advanced disease, the aromatase inhibitors are poised to establish their place in the adjuvant therapy of postmenopausal receptor-positive breast cancer." | 4.81 | Preliminary data from ongoing adjuvant aromatase inhibitor trials. ( Goss, PE, 2001) |
| "A consecutive cohort of ER( +)/HER2( -) advanced breast cancer patients who received palbociclib between 2017 and 2018 was analyzed." | 3.96 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. ( Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J, 2020) |
| "To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -positive breast cancer." | 3.78 | Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. ( A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L, 2012) |
| "A gene expression signature derived from ER(+) breast cancer cells with acquired hormone independence predicted tumor response to aromatase inhibitors and associated with clinical markers of resistance to tamoxifen." | 3.77 | A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. ( Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H, 2011) |
| "We conducted a prospective study including postmenopausal early breast cancer patients receiving either an aromatase inhibitor (AI) or tamoxifen." | 3.77 | Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. ( Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H, 2011) |
| "These data suggest that AEE788 plus letrozole in breast cancer overexpressing HER2 may provide superior anti-tumour activity, compared with single agents." | 3.76 | EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy. ( Dowsett, M; Evans, AH; Evans, DB; Farmer, I; Johnston, SR; Martin, LA; Pancholi, S; Thornhill, A, 2010) |
| "Taken together, data indicate that SERMs/antiestrogens and aromatase inhibitors exhibit opposed effects on the ER expression of breast cancer cells: tamoxifen and fulvestrant up-regulate ERalpha expression, while aromatase inhibitors increase ERbeta expression, which may contribute to the aromatase inhibitors' therapeutic superiority over antiestrogens." | 3.75 | Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells. ( Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P, 2009) |
| "Endocrine agents, such as letrozole, are established in the treatment of hormone-dependent breast cancer." | 3.75 | Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. ( Anderson, TJ; Dixon, JM; Evans, DB; Krause, A; Larionov, A; Miller, WR; Renshaw, L; Sing, T; Walker, JR, 2009) |
| "Letrozole after 5 years of adjuvant tamoxifen results in a significant reduction in risk of recurrence from estrogen receptor (ER) positive breast cancer." | 3.74 | Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. ( Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C, 2007) |
| "Genistein (GEN), a soy isoflavone, stimulates growth of estrogen-dependent human tumor cells (MCF-7) in a preclinical mouse model for postmenopausal breast cancer." | 3.74 | Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. ( Doerge, DR; Hartman, JA; Helferich, WG; Ju, YH; Kwak, J; Woodling, KA, 2008) |
| "In Breast International Group (BIG) 1-98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole versus tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer, letrozole significantly improved disease-free survival by 19% and reduced risk of breast cancer recurrence by 28% and distant recurrence by 27%." | 3.74 | Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. ( Barghout, V; Delea, TE; Karnon, J; Papo, NL; Sofrygin, O; Thomas, SK, 2007) |
| "Five years with the aromatase inhibitors letrozole or anastrozole is clinically superior to 5 years tamoxifen in postmenopausal women with early breast cancer." | 3.74 | Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. ( Barghout, V; Delea, T; Karnon, J, 2008) |
| "Two third-generation aromatase inhibitors, letrozole and anastrozole, and the antiestrogen tamoxifen, were compared for growth-inhibiting activity in two estrogen receptor (ER)-positive aromatase-overexpressing human breast cancer cell lines, MCF-7aro and T-47Daro." | 3.73 | Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. ( Chen, S; Itoh, T; Kijima, I, 2005) |
| "To compare the efficiency of adjuvant therapy with aromatase inhibitors or with tamoxifen in postmenopausal women with operable breast cancer and positive estrogen receptors." | 3.73 | Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. ( Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C, 2006) |
| "To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmenopausal breast cancer." | 3.72 | Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L, 2004) |
| "The antiestrogen tamoxifen has potent activity against estrogen receptor-positive breast cancer, but two nonsteroidal aromatase inhibitors, letrozole and anastrozole, show considerable advantages over tamoxifen with respect to patient survival and tolerability." | 3.72 | Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A, 2004) |
| "High-dose estrogen was generally considered the endocrine therapy of choice for postmenopausal women with breast cancer prior to the introduction of tamoxifen." | 3.71 | Estrogen as therapy for breast cancer. ( Ingle, JN, 2002) |
| "To determine the effects of aromatase inhibitors on oestrogen uptake, in situ aromatase activity and endogenous oestrogens in the breast, postmenopausal women with large primary ER-rich breast cancers have been treated neoadjuvantly for 3 months with either letrozole (2." | 3.71 | Local endocrine effects of aromatase inhibitors within the breast. ( Dixon, JM; Miller, WR, 2001) |
| "Postmenopausal women with large primary oestrogen receptor-rich (>20 fmol/mg protein or 80 histoscore) breast cancers have been treated neoadjuvantly with either letrozole (2." | 3.71 | Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. ( Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR, 2001) |
| "Put-analysis in 40 patients with breast cancer, to chanalicular infiltrated, eligible were treated in a prospective study, to double blind person, using per os: letrozol, 2." | 2.76 | [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer]. ( Amador, DD; Font López, KC; Novoa Vargas, A, 2011) |
| "Letrozole is a new highly selective and potent aromatase inhibitor." | 2.68 | A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. ( Camoriano, JK; Gerstner, JB; Gesme, DH; Hartmann, LC; Hatfield, AK; Ingle, JN; Johnson, PA; Loprinzi, CL; Mailliard, JA; Suman, VJ, 1997) |
| "Early hormone-receptor-positive breast cancer is a chronic relapsing disease that can remain clinically silent for many years." | 2.49 | Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. ( Goss, PE; Higgins, MJ; Liedke, PE, 2013) |
| "Given the common hormonal dependence of breast cancer and the potential synergistic effect of these two treatment modalities, this strategy has been increasing in the adjuvant setting." | 2.45 | [Adjuvant breast cancer treatment with hormono-radiotherapy]. ( Azria, D; Belkacémi, Y; Gligorov, J; Jacot, W; Ozsahin, M; Romieu, G; Zaman, K, 2009) |
| "Women with early breast cancer are exposed to an ongoing risk of relapse, even after successful surgical resection of the primary tumor and, where given, radiotherapy." | 2.44 | Reducing the risk of late recurrence in hormone-responsive breast cancer. ( Cufer, T, 2007) |
| "Letrozole has greater potency than other AIs, including anastrozole, exemestane, formestane, and aminoglutethimide." | 2.44 | The discovery and mechanism of action of letrozole. ( Bhatnagar, AS, 2007) |
| "Breast cancer is a leading cause of cancer death among women worldwide." | 2.44 | Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer. ( Dodwell, D; Williamson, D, 2008) |
| "Letrozole has also been used in advanced breast cancer, both as second-line hormone treatment following tamoxifen failure, and more recently as first-line therapy." | 2.41 | Anti-tumor effects of letrozole. ( Anderson, TJ; Dixon, JM; Miller, WR, 2002) |
| "Thus, management of metastatic breast cancer has largely shifted from surgeons to medical oncologists." | 2.40 | Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. ( Buzdar, AU; Roseman, BJ; Singletary, SE, 1997) |
| "Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks." | 2.40 | Use of aromatase inhibitors in breast carcinoma. ( Harvey, HA; Santen, RJ, 1999) |
| "The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown." | 1.39 | Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. ( Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P, 2013) |
| "Expression of aromatase in breast cancer tissue is driven by different promoters than those in noncancer tissues; thus, suppression of aromatase expression in cancer tissues through the down-regulation of breast tumor-specific promoters would reduce the side effects associated with whole-body suppression of estrogen biosynthesis by AIs." | 1.36 | The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. ( Chen, S; Evans, D; Kijima, I; Ye, J, 2010) |
| "Endocrine therapy in the setting of breast cancer has undoubtedly advanced clinical outcomes in this disease, but treatment with endocrine therapy is accompanied by a wide spectrum of side effects." | 1.36 | Cognitive changes associated with endocrine therapy for breast cancer. ( Agrawal, K; Mortimer, JE; Onami, S; Pal, SK, 2010) |
| "Letrozole was also effective in tumors failing to respond to tamoxifen, consistent with clinical findings." | 1.31 | Aromatase and COX-2 expression in human breast cancers. ( Blankenstein, MA; Blijham, GH; Brodie, AM; Chen, T; DeJong, PC; Elbers, JR; Fulton, A; Long, BJ; Lu, Q; Macpherson, N; Nortier, JW; Schipper, ME; Slee, PH; Thijssen, JH; van de Ven, J; van Gorp, JM, 2001) |
| "Letrozole (2." | 1.31 | Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. ( Chen, G; Cohen, MH; Johnson, JR; Li, N; Pazdur, R, 2002) |
| "MCF-7, human breast cancer cells transfected with the aromatase gene, inoculated into ovariectomized nude mice are able to synthesize sufficient estrogens to enhance cell proliferation and the development of tumors." | 1.30 | Intratumoral aromatase model: the effects of letrozole (CGS 20267). ( Brodie, A; Liu, Y; Lu, Q; Wang, J; Yue, W, 1998) |
| "Both mammary adipose tissue and breast cancers have the ability to aromatize androgens into oestrogens." | 1.30 | Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. ( Miller, WR, 1999) |
| "Letrozole was found to be a highly potent inhibitor of tumor proliferation and more effective than tamoxifen." | 1.30 | Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. ( Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (12.59) | 18.2507 |
| 2000's | 85 (62.96) | 29.6817 |
| 2010's | 31 (22.96) | 24.3611 |
| 2020's | 2 (1.48) | 2.80 |
| Authors | Studies |
|---|---|
| Vaklavas, C | 1 |
| Roberts, BS | 1 |
| Varley, KE | 1 |
| Lin, NU | 1 |
| Liu, MC | 1 |
| Rugo, HS | 1 |
| Puhalla, S | 1 |
| Nanda, R | 1 |
| Storniolo, AM | 2 |
| Carey, LA | 1 |
| Saleh, MN | 1 |
| Li, Y | 1 |
| Delossantos, JF | 1 |
| Grizzle, WE | 1 |
| LoBuglio, AF | 1 |
| Myers, RM | 1 |
| Forero-Torres, A | 1 |
| Ham, A | 1 |
| Kim, MH | 1 |
| Kim, GM | 1 |
| Kim, JH | 1 |
| Kim, JY | 1 |
| Park, HS | 1 |
| Park, S | 1 |
| Cho, YU | 1 |
| Park, BW | 1 |
| Kim, SI | 1 |
| Sohn, J | 1 |
| Zhang, J | 1 |
| Huang, Y | 1 |
| Wang, C | 1 |
| He, Y | 1 |
| Zheng, S | 1 |
| Wu, K | 1 |
| Dellapasqua, S | 1 |
| Gray, KP | 1 |
| Munzone, E | 1 |
| Rubino, D | 1 |
| Gianni, L | 1 |
| Johansson, H | 1 |
| Viale, G | 2 |
| Ribi, K | 1 |
| Bernhard, J | 1 |
| Kammler, R | 1 |
| Maibach, R | 1 |
| Rabaglio-Poretti, M | 1 |
| Ruepp, B | 1 |
| Di Leo, A | 1 |
| Coates, AS | 4 |
| Gelber, RD | 4 |
| Regan, MM | 1 |
| Goldhirsch, A | 4 |
| Colleoni, M | 2 |
| Di Lauro, L | 1 |
| Vici, P | 1 |
| Del Medico, P | 1 |
| Laudadio, L | 1 |
| Tomao, S | 1 |
| Giannarelli, D | 2 |
| Pizzuti, L | 1 |
| Sergi, D | 1 |
| Barba, M | 1 |
| Maugeri-Saccà, M | 1 |
| Strasser-Weippl, K | 1 |
| Badovinac-Crnjevic, T | 1 |
| Fan, L | 2 |
| Goss, PE | 10 |
| Ingle, JN | 10 |
| Kasum, M | 1 |
| Šimunić, V | 1 |
| Orešković, S | 1 |
| Beketić-Orešković, L | 1 |
| Liedke, PE | 2 |
| Isakoff, SJ | 1 |
| St Louis, J | 1 |
| Ryan, PD | 1 |
| Nicolini, A | 1 |
| Rossi, G | 1 |
| Ferrari, P | 1 |
| Carpi, A | 1 |
| Serrano, C | 1 |
| Nucci, MR | 1 |
| Tirumani, SH | 1 |
| Raut, CP | 1 |
| George, S | 1 |
| Blok, EJ | 1 |
| Derks, MG | 1 |
| van der Hoeven, JJ | 1 |
| van de Velde, CJ | 1 |
| Kroep, JR | 1 |
| Jia, X | 1 |
| Hong, Q | 1 |
| Lei, L | 2 |
| Li, D | 1 |
| Li, J | 1 |
| Mo, M | 1 |
| Wang, Y | 1 |
| Shao, Z | 2 |
| Shen, Z | 1 |
| Cheng, J | 2 |
| Liu, G | 2 |
| Mangini, NS | 1 |
| Wesolowski, R | 1 |
| Ramaswamy, B | 1 |
| Lustberg, MB | 1 |
| Berger, MJ | 1 |
| Sabnis, GJ | 2 |
| Macedo, LF | 2 |
| Goloubeva, O | 1 |
| Schayowitz, A | 1 |
| Brodie, AM | 5 |
| Vaidya, JS | 1 |
| Ju, YH | 1 |
| Doerge, DR | 1 |
| Woodling, KA | 1 |
| Hartman, JA | 1 |
| Kwak, J | 1 |
| Helferich, WG | 1 |
| Nagykálnai, T | 2 |
| Foster, PA | 1 |
| Chander, SK | 1 |
| Newman, SP | 1 |
| Woo, LW | 1 |
| Sutcliffe, OB | 1 |
| Bubert, C | 1 |
| Zhou, D | 1 |
| Chen, S | 4 |
| Potter, BV | 1 |
| Reed, MJ | 1 |
| Purohit, A | 1 |
| Wardley, AM | 1 |
| Miller, WR | 7 |
| Larionov, A | 1 |
| Renshaw, L | 3 |
| Anderson, TJ | 3 |
| Walker, JR | 1 |
| Krause, A | 1 |
| Sing, T | 1 |
| Evans, DB | 2 |
| Dixon, JM | 6 |
| Azria, D | 1 |
| Jacot, W | 1 |
| Gligorov, J | 1 |
| Belkacémi, Y | 1 |
| Zaman, K | 1 |
| Romieu, G | 1 |
| Ozsahin, M | 1 |
| Smollich, M | 1 |
| Götte, M | 1 |
| Fischgräbe, J | 1 |
| Radke, I | 1 |
| Kiesel, L | 1 |
| Wülfing, P | 1 |
| Glück, S | 1 |
| Guarneri, V | 1 |
| Briot, K | 1 |
| Tubiana-Hulin, M | 1 |
| Bastit, L | 1 |
| Kloos, I | 1 |
| Roux, C | 1 |
| Sabnis, G | 1 |
| Brodie, A | 4 |
| Evans, AH | 1 |
| Pancholi, S | 1 |
| Farmer, I | 1 |
| Thornhill, A | 1 |
| Johnston, SR | 1 |
| Dowsett, M | 9 |
| Martin, LA | 1 |
| Ye, J | 1 |
| Kijima, I | 2 |
| Evans, D | 1 |
| Agrawal, K | 1 |
| Onami, S | 1 |
| Mortimer, JE | 1 |
| Pal, SK | 1 |
| Lintermans, A | 1 |
| Van Calster, B | 1 |
| Van Hoydonck, M | 1 |
| Pans, S | 1 |
| Verhaeghe, J | 1 |
| Westhovens, R | 1 |
| Henry, NL | 2 |
| Wildiers, H | 1 |
| Paridaens, R | 4 |
| Dieudonné, AS | 1 |
| Leunen, K | 1 |
| Morales, L | 1 |
| Verschueren, K | 1 |
| Timmerman, D | 1 |
| De Smet, L | 1 |
| Vergote, I | 1 |
| Christiaens, MR | 1 |
| Neven, P | 1 |
| Miller, TW | 1 |
| Balko, JM | 1 |
| Ghazoui, Z | 1 |
| Dunbier, A | 1 |
| Anderson, H | 1 |
| González-Angulo, AM | 1 |
| Mills, GB | 1 |
| Wu, H | 1 |
| Shyr, Y | 1 |
| Arteaga, CL | 1 |
| Hong, Y | 1 |
| Rashid, R | 1 |
| Landherr, L | 1 |
| Mészáros, E | 1 |
| Novoa Vargas, A | 1 |
| Font López, KC | 1 |
| Amador, DD | 1 |
| Azzouz, F | 1 |
| Desta, Z | 1 |
| Li, L | 1 |
| Nguyen, AT | 1 |
| Lemler, S | 1 |
| Hayden, J | 1 |
| Tarpinian, K | 1 |
| Yakim, E | 1 |
| Flockhart, DA | 1 |
| Stearns, V | 1 |
| Hayes, DF | 1 |
| Mehta, NR | 1 |
| Wurz, GT | 1 |
| Burich, RA | 1 |
| Greenberg, BE | 1 |
| Griffey, S | 1 |
| Gutierrez, A | 1 |
| Bell, KE | 1 |
| McCall, JL | 1 |
| Wolf, M | 1 |
| DeGregorio, M | 1 |
| Yu, KD | 1 |
| Zhou, Y | 1 |
| Liu, GY | 1 |
| Li, B | 1 |
| He, PQ | 1 |
| Zhang, HW | 1 |
| Lou, LH | 1 |
| Wang, XJ | 1 |
| Wang, S | 1 |
| Tang, JH | 1 |
| Liu, YH | 1 |
| Wang, X | 2 |
| Jiang, ZF | 1 |
| Ma, LW | 1 |
| Gu, L | 1 |
| Cao, MZ | 1 |
| Zhang, QY | 1 |
| Wang, SM | 1 |
| Su, FX | 1 |
| Zheng, H | 1 |
| Li, HY | 1 |
| Tang, LL | 1 |
| Sun, SR | 1 |
| Liu, JP | 1 |
| Shao, ZM | 1 |
| Shen, ZZ | 1 |
| Folkerd, EJ | 1 |
| A'Hern, RP | 1 |
| Ligibel, JA | 1 |
| Winer, EP | 1 |
| Higgins, MJ | 1 |
| Xu, J | 1 |
| Sun, Y | 1 |
| Zhang, Y | 2 |
| Pan, L | 1 |
| Long, BJ | 4 |
| Jelovac, D | 4 |
| Thiantanawat, A | 2 |
| Smith, MR | 1 |
| Kaufman, D | 1 |
| George, D | 1 |
| Oh, WK | 1 |
| Kazanis, M | 1 |
| Manola, J | 1 |
| Kantoff, PW | 1 |
| Lipton, A | 2 |
| Ali, SM | 1 |
| Leitzel, K | 1 |
| Demers, L | 1 |
| Harvey, HA | 4 |
| Chaudri-Ross, HA | 1 |
| Brady, C | 2 |
| Wyld, P | 1 |
| Carney, W | 1 |
| Lønning, PE | 1 |
| Geisler, J | 1 |
| Bhatnager, A | 1 |
| Rose, C | 1 |
| Mouridsen, H | 4 |
| Gershanovich, M | 1 |
| Lønning, P | 1 |
| Pfister, C | 1 |
| Martoni, A | 1 |
| Zamagni, C | 1 |
| Bryant, J | 1 |
| Wolmark, N | 1 |
| Burstein, HJ | 1 |
| Martino, S | 4 |
| Robert, NJ | 4 |
| Muss, HB | 5 |
| Piccart, MJ | 4 |
| Castiglione, M | 3 |
| Tu, D | 4 |
| Shepherd, LE | 4 |
| Pritchard, KI | 5 |
| Livingston, RB | 3 |
| Davidson, NE | 3 |
| Norton, L | 3 |
| Perez, EA | 4 |
| Abrams, JS | 3 |
| Therasse, P | 1 |
| Palmer, MJ | 4 |
| Pater, JL | 4 |
| Brodie, AH | 1 |
| Long, B | 2 |
| Ellis, MJ | 2 |
| Rosen, E | 1 |
| Dressman, H | 1 |
| Marks, J | 1 |
| Shahab, N | 1 |
| Kawakami, M | 1 |
| Saji, S | 1 |
| Toi, M | 2 |
| Handratta, V | 2 |
| MacPherson, N | 2 |
| Ragaz, J | 1 |
| Goloubeva, OG | 2 |
| Morandi, P | 1 |
| Rouzier, R | 1 |
| Altundag, K | 1 |
| Buzdar, AU | 3 |
| Theriault, RL | 1 |
| Hortobagyi, G | 1 |
| Macedo, L | 1 |
| de Cremoux, P | 1 |
| Diéras, V | 1 |
| Poupon, MF | 1 |
| Magdelénat, H | 1 |
| Sigal-Zafrani, B | 2 |
| Fourquet, A | 1 |
| Pierga, JY | 1 |
| Thürlimann, B | 4 |
| Senn, HJ | 1 |
| Bertelli, G | 1 |
| Garrone, O | 1 |
| Bertolotti, L | 1 |
| Occelli, M | 1 |
| Conforti, S | 1 |
| Marzano, N | 1 |
| Febbraro, A | 1 |
| Carlini, P | 2 |
| Liossi, C | 1 |
| Del Mastro, L | 2 |
| Leonard, RC | 2 |
| Bria, E | 1 |
| Ferretti, G | 1 |
| Felici, A | 1 |
| Papaldo, P | 1 |
| Fabi, A | 1 |
| Nisticò, C | 1 |
| Di Cosimo, S | 1 |
| Ruggeri, EM | 1 |
| Milella, M | 1 |
| Mottolese, M | 1 |
| Terzoli, E | 1 |
| Cognetti, F | 1 |
| Itoh, T | 1 |
| Keshaviah, A | 3 |
| Mauriac, L | 3 |
| Forbes, JF | 3 |
| Castiglione-Gertsch, M | 3 |
| Rabaglio, M | 2 |
| Smith, I | 3 |
| Wardley, A | 3 |
| Wardly, A | 1 |
| Price, KN | 3 |
| Swain, SM | 1 |
| Michaud, LB | 1 |
| Scott, LJ | 1 |
| Keam, SJ | 1 |
| Higa, GM | 1 |
| Lane, HA | 1 |
| Lebwohl, D | 1 |
| Gil, JM | 1 |
| Rubio-Terrés, C | 1 |
| Del Castillo, A | 1 |
| González, P | 1 |
| Canorea, F | 1 |
| Maciá Escalante, S | 1 |
| Pons Sanz, V | 1 |
| Rodríguez Lescure, A | 1 |
| Ballester Navarro, I | 1 |
| Carrato Mena, A | 1 |
| Manquez, ME | 1 |
| Brown, MM | 1 |
| Shields, CL | 1 |
| Shields, JA | 1 |
| Guo, Z | 1 |
| Tilghman, SL | 1 |
| Qiu, Y | 1 |
| This, P | 1 |
| de la Rochefordière, A | 1 |
| Bredart, A | 1 |
| Asselain, B | 1 |
| Poinsot, R | 1 |
| Dolbeault, S | 1 |
| Mauri, D | 1 |
| Pavlidis, N | 1 |
| Polyzos, NP | 1 |
| Ioannidis, JP | 1 |
| Kennecke, HF | 1 |
| Olivotto, IA | 1 |
| Speers, C | 1 |
| Norris, B | 1 |
| Chia, SK | 1 |
| Bryce, C | 1 |
| Gelmon, KA | 1 |
| Láng, I | 2 |
| Chirgwin, J | 1 |
| Nogaret, JM | 2 |
| Pienkowski, T | 1 |
| Jakobsen, EH | 1 |
| Jänicke, F | 1 |
| Debled, M | 1 |
| Monnier, A | 1 |
| Zabaznyi, N | 1 |
| Arriola, E | 1 |
| Hui, E | 1 |
| Smith, IE | 3 |
| Delea, TE | 2 |
| Karnon, J | 3 |
| Sofrygin, O | 2 |
| Thomas, SK | 1 |
| Papo, NL | 1 |
| Barghout, V | 2 |
| Delea, T | 1 |
| El-Ouagari, K | 1 |
| Cufer, T | 1 |
| Bhatnagar, AS | 1 |
| Ma, C | 2 |
| Koeberle, D | 1 |
| Thuerlimann, B | 1 |
| O'Shaughnessy, J | 1 |
| Harbeck, N | 1 |
| Haidinger, R | 1 |
| Ellis, M | 1 |
| Dodwell, D | 1 |
| Williamson, D | 1 |
| Eisen, A | 1 |
| Trudeau, M | 1 |
| Shelley, W | 1 |
| Messersmith, H | 1 |
| Chow, LW | 1 |
| Yip, AY | 1 |
| Loo, WT | 1 |
| Chapman, JA | 1 |
| Meng, D | 1 |
| Shepherd, L | 1 |
| Parulekar, W | 1 |
| Palmer, M | 1 |
| Yu, C | 1 |
| Carpenter, R | 1 |
| Cameron, DA | 4 |
| Whelan, TJ | 1 |
| He, Z | 1 |
| Aapro, M | 1 |
| Antognelli, C | 1 |
| Del Buono, C | 1 |
| Baldracchini, F | 1 |
| Talesa, V | 1 |
| Cottini, E | 1 |
| Brancadoro, C | 1 |
| Zucchi, A | 1 |
| Mearini, E | 1 |
| Barnadas, A | 1 |
| Gil, M | 1 |
| Sánchez-Rovira, P | 1 |
| Llombart, A | 1 |
| Adrover, E | 1 |
| Estevez, LG | 1 |
| de la Haba, J | 1 |
| Calvo, L | 1 |
| Goyal, S | 1 |
| Puri, T | 1 |
| Julka, PK | 1 |
| Rath, GK | 1 |
| Demers, LM | 1 |
| Kambic, KB | 1 |
| Grossberg, H | 1 |
| Adlercruetz, H | 1 |
| Trunet, PF | 1 |
| Santen, RJ | 2 |
| Lee, K | 1 |
| Macaulay, VM | 1 |
| Detre, S | 1 |
| Rowlands, M | 1 |
| Grimshaw, R | 1 |
| Johnson, PA | 1 |
| Suman, VJ | 2 |
| Gerstner, JB | 1 |
| Mailliard, JA | 1 |
| Camoriano, JK | 1 |
| Gesme, DH | 1 |
| Loprinzi, CL | 1 |
| Hatfield, AK | 1 |
| Hartmann, LC | 1 |
| Roseman, BJ | 1 |
| Singletary, SE | 1 |
| Lu, Q | 3 |
| Liu, Y | 2 |
| Wang, JP | 1 |
| Yue, W | 2 |
| Wang, J | 1 |
| Norton, A | 1 |
| Love, CD | 1 |
| Bellamy, C | 1 |
| Coombes, RC | 1 |
| Harper-Wynne, C | 1 |
| Jordan, VC | 1 |
| Tekmal, RR | 1 |
| Kirma, N | 1 |
| Gill, K | 1 |
| Fowler, K | 1 |
| Crucitta, E | 1 |
| Lorusso, V | 1 |
| Attolico, M | 1 |
| Sambiasi, D | 1 |
| Mazzei, A | 1 |
| De Lena, M | 1 |
| Hamilton, A | 1 |
| Volm, M | 1 |
| Fulton, A | 1 |
| Chen, T | 1 |
| DeJong, PC | 1 |
| Blankenstein, MA | 1 |
| Nortier, JW | 1 |
| Slee, PH | 1 |
| van de Ven, J | 1 |
| van Gorp, JM | 1 |
| Elbers, JR | 1 |
| Schipper, ME | 1 |
| Blijham, GH | 1 |
| Thijssen, JH | 1 |
| Cohen, MH | 1 |
| Johnson, JR | 1 |
| Li, N | 1 |
| Chen, G | 1 |
| Pazdur, R | 1 |
| Illiger, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Open Label Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer[NCT00161291] | Phase 2 | 28 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer[NCT02005887] | Phase 2 | 51 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00004205] | Phase 3 | 8,028 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| A Randomised Effectiveness-implementation Trial for Evaluating Dietary and Manual Treatment With Osteopathic Techniques on Quality of Life and on Modulation of the Inflammatory State of Patients Diagnosed With Breast Cancer Undergoing Antiestrogenic Hormo[NCT06164119] | 600 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| Development and Evaluation of a Therapeutic Education Intervention Focused on the Accession of Patients Treated With Hormonal Therapy in the Management of Breast Cancer: PEPs Hormonotherapy[NCT02300675] | 352 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| A Prospective, Multicentre, Controlled, Observational Study to Evaluate the Performance of Patient Support Programme (PSP) in Improving Patient Adherence With Adjuvant Aromatase Inhibitors (AI) Medication for Postmenopausal, Early Stage Breast Cancer[NCT00769080] | 524 participants (Actual) | Observational | 2008-09-30 | Completed | |||
| A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Meta[NCT02947685] | Phase 3 | 496 participants (Anticipated) | Interventional | 2017-06-21 | Active, not recruiting | ||
| LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer[NCT03917082] | Phase 2 | 290 participants (Anticipated) | Interventional | 2019-09-23 | Active, not recruiting | ||
| A Prospective Randomized Feasibility and Phase II Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors.[NCT00851110] | Phase 2 | 50 participants (Anticipated) | Interventional | 2004-10-31 | Terminated | ||
| Aromatase Inhibitors: Skeletal Effects and the Role of CYP19 Gene Polymorphisms[NCT00603967] | 151 participants (Actual) | Interventional | 2006-03-31 | Completed | |||
| A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen[NCT00003140] | Phase 3 | 5,187 participants (Actual) | Interventional | 1998-08-24 | Completed | ||
| Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)[NCT00712985] | Phase 3 | 18 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy[NCT02394496] | Phase 3 | 396 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
| PHASE III RANDOMIZED CONTROL CASE STUDY OF LETROZOLE IN WOMEN WITH HEAVILY PRETREATED OVARIAN CANCER (MITO 32)[NCT04421547] | Phase 3 | 236 participants (Anticipated) | Interventional | 2020-06-01 | Not yet recruiting | ||
| Placebo-controlled Evaluation of the Homeopathic Drug BRN01 for the Treatment of Hot Flashes in Women With Non Metastatic Breast Cancer Treated by Adjuvant Hormonal Therapy[NCT01246427] | Phase 3 | 138 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial[NCT03295916] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer[NCT02955394] | Phase 2 | 61 participants (Actual) | Interventional | 2017-09-21 | Active, not recruiting | ||
| Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study[NCT01016665] | 71 participants (Actual) | Interventional | 2005-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Based on WHO tumor measurement and response criteria [1], measured from the start of treatment across all time points until disease progression or the end of 6 cycles of neoadjuvant therapies, whichever comes first. Response was determined by the IBCSG Head of Medical Affairs. An internal review (IR) form was created to record the final determination on best overall response. Confirmation of partial or complete response by an additional scan was not required in this trial. Best overall response was assessed based on changes in tumor size from baseline to the assessments after 3 and after 6 cycles (denoted as day 1 of cycle 4 and prior to surgery respectively) as measured physically by caliper or ruler and as measured by breast tumor imaging (i.e., bilateral mammography and breast ultrasound). (NCT02005887)
Timeframe: From day 1 of cycle 1 across all time points until disease progression
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A: Triptorelin + Letrozol | 46.2 |
| Arm B: Degarelix + Letrozol | 44.0 |
The percent change in Ki67 expression from pre-treatment diagnostic (baseline) biopsy to surgery, calculated as (surgery-baseline)/baseline*100. (NCT02005887)
Timeframe: Before day1 of cycle 1 and surgery
| Intervention | percentage change (Median) |
|---|---|
| Arm A: Triptorelin + Letrozol | -10.0 |
| Arm B: Degarelix + Letrozol | -8.0 |
The patient-reported symptoms (PRS) will be assessed using the Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-ES) comprising 18 items (each has score range from 0 to 4) with a possible minimum total score of 0 and maximum total score of 72 (72 is best). Functional Assessment of Chronic Illness Therapy (FACIT) guidelines will be used for scoring and interpretation of the FACT-ES total score. (NCT02005887)
Timeframe: At baseline, day 1 of cycle 2 and cycle 4 and prior to surgery; cycle 4 reported
| Intervention | units on a scale (Number) |
|---|---|
| Arm A: Triptorelin + Letrozol | 64 |
| Arm B: Degarelix + Letrozol | 62 |
Whether or not patient undergoes BCS (per Surgery form). (NCT02005887)
Timeframe: During surgery, an average of 2 hours
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A: Triptorelin + Letrozol | 42.3 |
| Arm B: Degarelix + Letrozol | 52.2 |
The number of lymph nodes assessed at surgery minus the number of positives nodes identified, equal to zero. (NCT02005887)
Timeframe: During surgery, an average of 2 hours
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A: Triptorelin + Letrozol | 34.6 |
| Arm B: Degarelix + Letrozol | 43.5 |
Preoperative Endocrine Prognostic Index (PEPI) is the sum of the risk points (tumor size, nodal status, Ki67 level, ER status) with a 0-12 score representing the best prognostic feature (0 being the best score; 12 being the worst score), as previously determined to be associated with recurrence-free survival. (NCT02005887)
Timeframe: After 24 weeks or the time of surgery
| Intervention | scores on a scale (Median) |
|---|---|
| Arm A: Triptorelin + Letrozol | 6.5 |
| Arm B: Degarelix + Letrozol | 6.0 |
Time from the first injection of degarelix or triptorelin to the first assessment of centrally assessed 17-β-estradiol (E2) level in the range of optimal ovarian function suppression (≤2.72 pg/mL or ≤10 pmol/L) during the 6 cycles of neoadjuvant treatments. (NCT02005887)
Timeframe: up to 24 weeks
| Intervention | days (Median) |
|---|---|
| Arm A: Triptorelin + Letrozol | 14 |
| Arm B: Degarelix + Letrozol | 3 |
17 women with early breast cancer receiving adjuvant Aromatase Inhibitor (AI) therapy were treated with a single 5 mg IV dose of zoledronic acid. Urine and serum NTx and serum CTx were measured at baseline and month 12. (NCT00712985)
Timeframe: One year
| Intervention | participants (Number) |
|---|---|
| Zoledronic Acid 5 mg IV | 13 |
The strength of AR signaling was measured by the percentage of downstream AR-regulated genes that were expressed. (NCT02955394)
Timeframe: 16 Weeks
| Intervention | percentage of genes expressed (Median) |
|---|---|
| Fulvestrant Without Enzalutamide | 85 |
| Fulvestrant With Enzalutamide | 80 |
Disease-free survival is defined as the time in months from the start of fulvestrant until documented disease progression or death. Complete and partial response for the single drug arm and combination of enzalutamide/fulvestrant arm separately. (NCT02955394)
Timeframe: 15 months
| Intervention | months (Median) |
|---|---|
| Fulvestrant Without Enzalutamide | 3.6 |
| Fulvestrant With Enzalutamide | 3.7 |
"The preoperative endocrine prognostic index (PEPI) is a validated measure of pathologic response to endocrine therapy. It is a model that combines estrogen receptor (ER) level, pathologic tumor site, nodal status, and Ki67 score at the time of surgery to predict subsequent risk of cancer recurrence.~PEPI scoring is typically discretized into three risk groups: 0 (low risk of recurrence and best outcome), 1-3 (intermediate risk), and >= 4 (high risk). This study was concerned only with the distinction between zero and non-zero PEPI scores. Zero is the minimum score, and there is no maximum score. Lower scores are better." (NCT02955394)
Timeframe: 16 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Fulvestrant Without Enzalutamide | 2 |
| Fulvestrant With Enzalutamide | 8 |
52 reviews available for letrozole and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradi | 2017 |
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neopla | 2013 |
Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemothera | 2013 |
Intermittent letrozole therapy for metastatic breast cancer: case reports and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinic | 2014 |
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitor | 2015 |
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; | 2015 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2008 |
Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Human | 2008 |
[Adjuvant breast cancer treatment with hormono-radiotherapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2009 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormona | 2010 |
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
[Aromatase inhibitors and arthralgia].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Brea | 2011 |
Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dru | 2013 |
Anti-tumor effects of letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clin | 2002 |
Development of aromatase inhibitors and their pharmacologic profile.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonis | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2003 |
Pharmacokinetics of third-generation aromatase inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug | 2003 |
Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme | 2003 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
[Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)].
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 2005 |
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2006 |
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2006 |
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2006 |
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2006 |
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Forecasting; H | 2006 |
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2006 |
Continuing with letrozole offers greater benefits.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Human | 2007 |
The discovery and mechanism of action of letrozole.
Topics: Aged; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
The patient experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Ch | 2007 |
Femara and the future: tailoring treatment and combination therapies with Femara.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitor | 2007 |
Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Fem | 2008 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
The control and biological importance of intratumoural aromatase in breast cancer.
Topics: Adenocarcinoma; Androgens; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aro | 1996 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormo | 1997 |
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 1998 |
Theoretical considerations for the ideal aromatase inhibitor.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 1998 |
Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; E | 1998 |
Drug and hormone interactions of aromatase inhibitors.
Topics: Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; E | 1999 |
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as | 1999 |
Aromatase inhibitors: a dose-response effect?
Topics: Aminoglutethimide; Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplas | 1999 |
Aromatase inhibitors and their use in the sequential setting.
Topics: Androstenedione; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase In | 1999 |
Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhib | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormo | 1999 |
New aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Toleran | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2001 |
26 trials available for letrozole and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2019 |
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2010 |
[Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modalit | 2011 |
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; | 2012 |
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; | 2012 |
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; | 2012 |
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; | 2012 |
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neo | 2012 |
Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Aromatase Inhibitors; Enzyme Inhibitors; | 2002 |
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disea | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2005 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2005 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2005 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2005 |
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2007 |
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitor | 2007 |
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Anal | 2008 |
Letrozole in the neoadjuvant setting: the P024 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Do | 2007 |
Letrozole in the neoadjuvant setting: the P024 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Do | 2007 |
Letrozole in the neoadjuvant setting: the P024 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Do | 2007 |
Letrozole in the neoadjuvant setting: the P024 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Do | 2007 |
Letrozole in the extended adjuvant setting: MA.17.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Ch | 2007 |
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Ch | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neopl | 2008 |
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Cardiovascular Disease | 2008 |
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chem | 2008 |
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast | 2008 |
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Coh | 2008 |
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Fe | 1995 |
A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedul | 1997 |
[Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Double-Blind Meth | 2002 |
58 other studies available for letrozole and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Li | 2020 |
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inh | 2013 |
Fertility preservation with ovarian stimulation protocols prior to cancer treatment.
Topics: Aromatase Inhibitors; Estrogen Antagonists; Female; Fertility Preservation; Gonadotropins; Humans; L | 2014 |
Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2014 |
Hormone dependency in metastatic low-grade leiomyosarcoma following uterine smooth muscle tumour of uncertain malignant potential.
Topics: Adult; Aromatase Inhibitors; Estrogen Replacement Therapy; Estrogens; Female; Humans; Hysterectomy; | 2014 |
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Diphosph | 2015 |
Stopping treatment can reverse acquired resistance to letrozole.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Pr | 2008 |
Method to test whether late extended letrozole, rather than self- selection, improves the outcome in patients with breast cancer who have completed 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2008 |
Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Topics: Animals; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Division; Cell Line, | 2008 |
A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Topics: Administration, Oral; Animals; Aromatase Inhibitors; Azasteroids; Breast Neoplasms; Cell Proliferati | 2008 |
Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biopsy; Breast Neoplasms; Drug Resistance, Neoplasm; Fe | 2009 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagoni | 2009 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2004 |
Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; | 2010 |
Breast cancer drug approved for new indication.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Approval; Drug Therapy, | 2010 |
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Cell Line, Tum | 2010 |
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
Topics: Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; CCAAT-Enhancer-Binding Protein-del | 2010 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2010 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplas | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; | 2011 |
Binding features of steroidal and nonsteroidal inhibitors.
Topics: Amino Acids; Androgens; Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Binding Si | 2011 |
L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors | 2012 |
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Ma | 2012 |
Aromatase inhibition in obese women: how much is enough?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2012 |
18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen | 2013 |
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Estr | 2002 |
Letrozole after tamoxifen for breast cancer--what is the price of success?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Le | 2003 |
Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Le | 2003 |
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Cell | 2003 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chem | 2004 |
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Dis | 2004 |
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line | 2004 |
Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female | 2005 |
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cel | 2005 |
Aromatase inhibitors--a triumph of translational oncology.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adju | 2005 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer : a viewpoint by Laura B. Michaud.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy | 2006 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Tria | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Primary hormone treatment in postmenopausal women with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemot | 2006 |
Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Topics: Androgen Receptor Antagonists; Androgens; Androstenedione; Aromatase; Breast Neoplasms; Cell Growth | 2006 |
Quality of life in a randomized control trial? Comments concerning MA 17.
Topics: Antineoplastic Agents, Hormonal; Bias; Breast Neoplasms; Chemotherapy, Adjuvant; Confounding Factors | 2006 |
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Br | 2007 |
Aromatase inhibitors and male breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Br | 2007 |
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cos | 2007 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Alteration of glyoxalase genes expression in response to testosterone in LNCaP and PC3 human prostate cancer cells.
Topics: Adenocarcinoma; Androgens; Aromatase Inhibitors; Base Sequence; Cell Line, Tumor; Enzyme Induction; | 2007 |
Excellent response to letrozole in brain metastases from breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Cranial Irrad | 2008 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Intratumoral aromatase model: the effects of letrozole (CGS 20267).
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; | 1998 |
Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultured; E | 1999 |
Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.
Topics: Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors | 1999 |
Aromatase and COX-2 expression in human breast cancers.
Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplas | 2001 |
Local endocrine effects of aromatase inhibitors within the breast.
Topics: Anastrozole; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultu | 2001 |
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estr | 2001 |
Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Enzyme Inhibitors; Fem | 2002 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Pha | 2002 |